chartexchange

NBY
NovaBay Pharmaceuticals, Inc.
stockNYSEAMERICAN

InactiveApr 2, 2026
1.95USD+22.642%(+0.36)637,597
Loading…
Loading…
Sector
Healthcare
Industry
Biotechnology
HQ
Emeryville, California, USA
Feb 23, 2026 · 1-for-5 (reverse)
NBY Profile

novabay pharmaceuticals $nby is a biopharmaceutical company focusing, commercializing and developing its non-antibiotic anti-infective products to address the unmet therapeutic needs of the global eye care market. novabay has two distinct product categories: the neutrox™ family of products, led by avenova™ for the eye care market, neutrophase® for wound care, and cellerx™ for the dermatology market; and aganocide® compounds, led by auriclosene™. novabay is commercializing avenova, a prescription lid and lash hygiene product for the management of the chronic eye conditions of blepharitis and meibomian gland dysfunction – also known as dry eye syndrome. these difficult-to-manage conditions affect approximately 30 million americans, with an annual market potential that novabay estimates at $500 million. novabay is gaining market traction with avenova through its 35-medical direct sales representatives under veteran leadership. avenova is available for order in 90% of all pharmacies across

NBY Performance
PeriodPriceDateChange